ArticleCancer discovery2022
Open access · greenAbstract read
In one paragraph
Article in Cancer discovery, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 88 papers.
0numbers the graph read from it
0cells of the map it votes in
88citing papers in PubMed
7.1field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
88 citing papers in PubMed, 110 citations in OpenAlex.
- Modeling lung adenocarcinoma using layer-by-layer nanoparticles mitigates innate immune cell activation.bioRxiv : the preprint server for biology · 2026Article
- SMARCA4, STK11, and KEAP1 co-inactivation associates with poor prognosis and upregulation of the TGF-β pathway in lung adenocarcinoma.Translational oncology · 2026Article
- The roles of chromatin remodeling and 3D genome organization in cancers: from mechanistic insights to emerging treatment options.Molecular cancer · 2026Review
- Role of chromatin remodeling and immunopharmacology in cancer therapy.Molecular medicine (Cambridge, Mass.) · 2026Review
- Osimertinib Resistance in EGFR-Mutated Non-Small Cell Lung Cancer: Mechanisms and Therapeutic Strategies.MedComm · 2026Review
- SMARCA4 deficiency contributes to platinum resistance in non-small cell lung cancer by activating the NF-κB-BIRC2/BIRC3 signaling axis.Journal of thoracic disease · 2026Article
- SMARCA4-deficient lung adenocarcinoma with oral cavity metastasis: a case report.BMC oral health · 2026Article
- Cell fate specification during respiratory development requires ARID1A-containing canonical BAF complex activity.Nature communications · 2026Article
- SMARCA4 Loss Promotes Late-Stage Tumor Progression in Nonneuroendocrine Small Cell Lung Cancer.Molecular cancer research : MCR · 2026Article
- Chromatin Accessibility in Cancer: Biological Functions, Mechanisms, Therapeutic Potential, and Future Directions.MedComm · 2026Review
- mSWI/SNF complex inhibition sensitizes KRAS-mutant lung cancers to targeted therapies via epithelial-mesenchymal subversion.bioRxiv : the preprint server for biology · 2026Article
- SMARCA4 deficiency in glioblastoma: Mitochondrial transfer from MSCs and the clinical dilemma in targeting the tumor microenvironment.Neoplasia (New York, N.Y.) · 2026Article
- Small intestinal SMARCA4-deficient undifferentiated carcinoma with intussusception: A case report.Oncology letters · 2026Article
- Bromodomain-Driven Regulation of Stem Cells: A Potential Target for Cancer Therapeutic Intervention.Stem cell reviews and reports · 2026Review
- Tumor suppressor genes and KRAS G12C inhibitor resistance in non-small cell lung cancer.iScience · 2026Review
- Stage IV SMARCA4-Deficient Undifferentiated Malignant Neoplasm With Primary Cutaneous Origin and Early Distant Metastases.Case reports in dermatological medicine · 2026Article
- First-Line Treatment of Advanced Thoracic SMARCA4-Deficient Undifferentiated Tumor: A Case Report and Review of the Literature.Case reports in oncological medicine · 2026Article
- Evolution of Cancer Metastases via Lineage Trans-Differentiation.Research (Washington, D.C.) · 2026Article
- Rare tongue base metastasis from SMARCA4-deficient undifferentiated non-small cell lung carcinoma: a case report.International journal of clinical and experimental pathology · 2026Article
- [Clinical Characteristics and Prognosis Analysis of Thoracic SMARCA4-deficient Undifferentiated Tumor versus SMARCA4-deficient Non-small Cell Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2025Article
28 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 6 institutions in 1 country.
Carla P ConcepcionKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts.
Sai Ma *Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts.
Lindsay M LaFave *Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts.ORCID 0000-0002-5203-4961
Arjun Bhutkar *Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts.
Manyuan LiuKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts.
Lydia P DeAngeloKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts.ORCID 0000-0002-0549-325X
Jonathan Y KimKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts.
Isabella Del PrioreKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts.
Adam J SchoenfeldThoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0002-2644-1416
Manon MillerKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts.
Vinay K KarthaDepartment of Stem Cell and Regenerative Biology, Harvard University, Cambridge, Massachusetts.
Peter M K WestcottKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts.ORCID 0000-0001-9436-4857
Francisco J Sánchez-RiveraCancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0002-8466-8563
Kevin MeliKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts.ORCID 0000-0002-9579-3829
Manav GuptaStem Cell Program, Division of Hematology/Oncology and Division of Respiratory Disease, Boston Children's Hospital, Boston, Massachusetts.ORCID 0000-0001-5163-2911
Roderick T BronsonDepartment of Pathology, Harvard Medical School, Boston, Massachusetts.
Gregory J RielyThoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Natasha RekhtmanDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0001-5801-3144
Charles M RudinThoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0001-5204-3465
Carla F KimStem Cell Program, Division of Hematology/Oncology and Division of Respiratory Disease, Boston Children's Hospital, Boston, Massachusetts.
Aviv RegevKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts.
Jason D BuenrostroDepartment of Stem Cell and Regenerative Biology, Harvard University, Cambridge, Massachusetts.
Tyler JacksKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts. tjacks@mit.edu.
Massachusetts Institute of Technology · USMemorial Sloan Kettering Cancer Center · USHarvard Stem Cell Institute · USBoston Children's Hospital · USBroad Institute · USHarvard University · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MVIRUS PRODUCTION COREP30CA014051 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI MATTHEW G. VANDER HEIDEN · 1985 to 2026
$93.9MUSE OF RETROVIRUS PROMOTER TRAP VECTORS TO IDENTIFY ONCOGENES AND ANTI-ONCOGENESP01CA042063 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI JACKS, TYLER E. · 1986 to 2021
$30.5MMechanisms of tumorigenesis in Brg1 mutant lung cancerR01CA216188 · NCI · BOSTON CHILDREN'S HOSPITAL · PI KIM, CARLA F., WONG, KWOK KIN · 2018 to 2022
$3.3MEPA EP-C-17-009NCI NIH HHS P01 CA042063NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA014051NCI NIH HHS R01 CA216188
Abstract
PubMed holds no abstract for this paper.
Indexed as
Cell Transformation, NeoplasticNeoplasm MetastasisAdenocarcinoma of LungAnimalsDisease Models, AnimalDNA HelicasesHumansLung NeoplasmsMiceNuclear ProteinsTranscription FactorsDNA HelicasesNuclear ProteinsSMARCA4 protein, humanTranscription Factors
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.